Factors CD10, cytokeratin 19 and staging-grading systems in predicting the prognosis of pancreatic neuroendocrine tumors (PNET)

Basit Öğe Kaydı
dc.contributor.authorUguz A.
dc.contributor.authorUnalp O.V.
dc.contributor.authorYeniay L.
dc.contributor.authorFarajov R.
dc.contributor.authorYoldas T.
dc.contributor.authorSezer T.O.
dc.contributor.authorIpek N.Y.
dc.contributor.authorNart D.
dc.contributor.authorYilmaz F.
dc.contributor.authorSozbilen M.
dc.contributor.authorCoker A.
dc.date.accessioned2019-10-27T08:24:27Z
dc.date.available2019-10-27T08:24:27Z
dc.date.issued2012
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective. This study was undertaken to examine prognostic factors in patients with pancreatic neuroendocrine tumors (PNET) undergoing surgical treatment to evaluate the prognostic value of recently introduced immunohistochemical staining methods of CD10 and cytokeratin 19. Materials and Methods. Tumors were classified on the basis of 2004 WHO Classification Guidelines and European Neuroendocrine Tumor Society (ENETS) grading system. Immunohistochemical staining with Ki- 67, CD10 and cytokeratin 19 was performed. Results. A total of 36 patients with a mean age of 53.7 ± 12.0 years were included. Overall, 33 patients had a long-term follow-up with 10 patients (30.3%) experiencing recurrence. Seven patients (21.1%) died. Clinical parameters that were associated with recurrence included liver metastasis at the time of surgery and extra-pancreatic invasion (p < 0.005). Positive surgical margins, extra-pancreatic invasion, and multi-focal disease were associated with reduced survival (p < 0.05). In addition, there was an association between survival and WHO 2004 classification (p < 0.05). Conclusions. Although vascular and peripancreatic invasion showed increased risk of recurrence, they were unrelated to survival. Of the histopathological examinations, Ki-67 and mitotic activity showed a correlation with both recurrence and survival, while immunohistochemical staining with cytokeratin 19 and CD 10 did not provide adequate prognostic information.en_US
dc.identifier.doi10.4183/aeb.2012.653
dc.identifier.endpage666en_US
dc.identifier.issn1841-0987
dc.identifier.issn1841-0987en_US
dc.identifier.issue4en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage653en_US
dc.identifier.urihttps://doi.org/10.4183/aeb.2012.653
dc.identifier.urihttps://hdl.handle.net/11454/26579
dc.identifier.volume8en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.relation.ispartofActa Endocrinologicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCD-10en_US
dc.subjectCytokeratin-19en_US
dc.subjectNeuroendocrine tumoren_US
dc.subjectPancreasen_US
dc.subjectPrognostic factorsen_US
dc.titleFactors CD10, cytokeratin 19 and staging-grading systems in predicting the prognosis of pancreatic neuroendocrine tumors (PNET)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu